Tesaro's Varubi Wins FDA Approval; Shares Up

Shares of Tesaro jumped about 10% on Sept. 2 on the news the FDA had approved the Waltham, MA firm's new drug application to market Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (CINV) in adults.

More from Alimentary/Metabolic

More from Therapy Areas